Henry Schein (HSIC)
(Delayed Data from NSDQ)
$70.37 USD
+0.14 (0.20%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $70.37 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$70.37 USD
+0.14 (0.20%)
Updated Nov 1, 2024 04:00 PM ET
After-Market: $70.37 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
A Value B Growth D Momentum A VGM
Zacks News
Here's Why You Should Invest in Henry Schein (HSIC) Stock
by Zacks Equity Research
Henry Schein's (HSIC) strategy to extend digital dentistry globally is encouraging. Recent acquisitions will strengthen its foothold in the high-potential dental market.
HSIC or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. MMSI: Which Stock Is the Better Value Option?
Henry Schein's 3 Investments to Fortify Dental Implant Arm
by Zacks Equity Research
Intra-Lock, Medentis Medical and Pro-Cam Implants jointly are likely to prove conducive to growth for Henry Schein's (HSIC) existing implant-based tooth replacement solutions line.
Henry Schein (HSIC) Down 2.4% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Medical - Dental Supplies Outlook: Long-Term Prospects Bright
by Zacks Equity Research
The ongoing digital transition is posing challenges to dental industry players in the wake of growing oral hygiene awareness and increasing incidence of dental diseases.
Henry Schein's (HSIC) Q2 Earnings Beat, '18 EPS View Up
by Zacks Equity Research
All four of Henry Schein's (HSIC) operating segments recorded strong year-over-year growth in Q2.
Henry Schein (HSIC) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Henry Schein (HSIC) delivered earnings and revenue surprises of 1.96% and 0.73%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Medical Product Stock Earnings on Aug 6: CAH, HSIC & More
by Zacks Equity Research
The Medical product market gains momentum owing to the recent two-year suspension of the controversial 2.3% Medical Device tax.
Can Dental Growth Drive Henry Schein's (HSIC) Q2 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) is strongly placed to gain from the ongoing trend of digitalization in the global dental market.
HSIC vs. ALGN: Which Stock Is the Better Value Option?
by Zacks Equity Research
HSIC vs. ALGN: Which Stock Is the Better Value Option?
What's in Store for GNC Holdings (GNC) This Earnings Season?
by Zacks Equity Research
GNC Holdings' (GNC) revenues are likely to decline on a year-over-year basis, owing to weakness in U.S. & Canada segments in Q2.
Will Edwards' (EW) Steady Overall Growth Drive Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences (EW) expected to gain from strength in all business segments and geographies in Q2.
Can Overall Growth Drive Align Technology (ALGN) Q2 Earnings?
by Zacks Equity Research
Align Technology (ALGN) likely to gain from strength in Invisalign space as well as Scanner and Service business in Q2.
Boston Scientific (BSX) Q2 Earnings: Is a Beat in Store?
by Zacks Equity Research
Boston Scientific (BSX) expects to consistently gain from impressive growth across all business lines and geographies.
HSIC or MMSI: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
HSIC vs. MMSI: Which Stock Is the Better Value Option?
BD Buys TVA Medical, To Provide Minimally Invasive Procedure
by Zacks Equity Research
The acquisition of TVA Medical will enable Becton, Dickinson (BDX) to treat patients with chronic kidney disease through minimally invasive procedures.
Henry Schein's JV With Internet Brands to Boost Dental Arm
by Zacks Equity Research
Henry Schein (HSIC) and Internet Brands' newly formed JV is likely to deliver integrated dental technology for improving practice management, marketing as well as patient communication.
Will Walgreens (WBA) Q3 Earnings Gain From Overall Strength?
by Zacks Equity Research
Walgreens Boots' (WBA) sales rise at the Retail Pharmacy USA segment on account of tie-ups along with strength in other businesses buoys optimism.
MedTech Overcomes Policy Hurdles, Long-Term Prospects Bright
by Zacks Equity Research
With the suspension of the controversial 2.3% medical device tax for another two years, the medical device industry is currently riding high on optimism.
Why is Henry Schein (HSIC) Down 1.1% Since its Last Earnings Report?
by Zacks Equity Research
Henry Schein (HSIC) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Henry Schein's (HSIC) Q1 Earnings Beat, '18 View Intact
by Zacks Equity Research
We currently await the completion of Henry Schein's (HSIC) planned spin-off of global Animal Health business. This business contributes nearly 30% to the company's top line.
Henry Schein's (HSIC) Q1 Earnings & Revenues Top Estimates
by Zacks Equity Research
Henry Schein's (HSIC) four global segments gained market share during Q1 and delivered solid earnings growth on back of the strategy to grow the business organically and through acquisitions.
Can Overall Growth Drive Henry Schein's (HSIC) Q1 Earnings?
by Zacks Equity Research
Henry Schein (HSIC) likely to gain on strength across all business segments in Q1.
Company News for Apr 24, 2018
by Zacks Equity Research
Companies in the news are: ALK,ASB,HSIC,HUM
Factors Setting Stage for CVS Health's (CVS) Q1 Earnings
by Zacks Equity Research
CVS Health (CVS) expects robust 2018 PBM selling season and strong Pharmacy Services segment to drive earnings in Q1.